ES2176235T3 - Pirazolitriazinas con actividad inhibidora de la interleuquina-1 y delfactor de necrosis tumoral. - Google Patents

Pirazolitriazinas con actividad inhibidora de la interleuquina-1 y delfactor de necrosis tumoral.

Info

Publication number
ES2176235T3
ES2176235T3 ES94906381T ES94906381T ES2176235T3 ES 2176235 T3 ES2176235 T3 ES 2176235T3 ES 94906381 T ES94906381 T ES 94906381T ES 94906381 T ES94906381 T ES 94906381T ES 2176235 T3 ES2176235 T3 ES 2176235T3
Authority
ES
Spain
Prior art keywords
alkyl
suitable substituent
pct
pirazolitriazinas
interleuquine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94906381T
Other languages
English (en)
Inventor
Yoshio Kawai
Hitoshi Yamazaki
Hirokazu Tanaka
Teruo Oku
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujisawa Pharmaceutical Co Ltd
Original Assignee
Fujisawa Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Pharmaceutical Co Ltd filed Critical Fujisawa Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2176235T3 publication Critical patent/ES2176235T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

NUEVOS DERIVADOS HETEROCICLICOS DE FORMULA (I) EN DONDE R{SUP,1} ES ARILO QUE PUEDE TENER SUSTITUYENTE(S) ADECUADO(S) O UN GRUPO HETEROCICLICO QUE PUEDE TENER SUSTITUYENTE(S) ADECUADO(S), R{SUP,2} ES ARILO QUE PUEDE TENER SUSTITUYENTE(S) ADECUADO(S) O UN GRUPO HETEROCICLICO QUE PUEDE TENER SUSTITUYENTE(S) ADECUADO(S), R{SUP,3} ES HIDROGENO O ACILO, R{SUP,4} ES HIDROGENO, ALKILO BAJO, CICLOALKILO(()BAJO()), CICLOALKILO(()BAJO())-ALKILO(()BAJO()), CARBOXIALKILO(()BAJO()), CARBOXIALKILO(()BAJO()) PROTEGIDO, ARALKILO(()BAJO(() QUE PUEDE TENER SUSTITUYENTE(S) ADECUADO(S), ARALKENILO(()BAJO()), TRICICLIALKILO UNIDO, UN GRUPO HETEROCICLICO QUE PUEDE TENER SUSTITUYENTE(S) ADECUADO(S), ACILO, O UN GRUPO DE FORMULA (B) (EN EL QUE A ES ALQUILENO BAJO), Y R{SUP,5} ES HIDROGENO O ALKILO BAJO, Y UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO QUE SON UTILES COMO INHIBIDORES DE INTERLEUQUINA-1 Y NECROSIS TUMORAL.
ES94906381T 1993-02-26 1994-02-09 Pirazolitriazinas con actividad inhibidora de la interleuquina-1 y delfactor de necrosis tumoral. Expired - Lifetime ES2176235T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939303993A GB9303993D0 (en) 1993-02-26 1993-02-26 New heterocyclic derivatives

Publications (1)

Publication Number Publication Date
ES2176235T3 true ES2176235T3 (es) 2002-12-01

Family

ID=10731142

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94906381T Expired - Lifetime ES2176235T3 (es) 1993-02-26 1994-02-09 Pirazolitriazinas con actividad inhibidora de la interleuquina-1 y delfactor de necrosis tumoral.

Country Status (20)

Country Link
US (1) US5670503A (es)
EP (1) EP0686156B1 (es)
JP (1) JP3569917B2 (es)
KR (1) KR100313615B1 (es)
CN (1) CN1041929C (es)
AT (1) ATE220677T1 (es)
AU (1) AU681625B2 (es)
CA (1) CA2156919A1 (es)
DE (1) DE69430988T2 (es)
DK (1) DK0686156T3 (es)
ES (1) ES2176235T3 (es)
GB (1) GB9303993D0 (es)
HU (1) HUT70832A (es)
IL (1) IL108562A (es)
MX (1) MX9401408A (es)
PT (1) PT686156E (es)
RU (1) RU2124517C1 (es)
TW (1) TW260669B (es)
WO (1) WO1994019350A1 (es)
ZA (1) ZA94787B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0913392B1 (en) 1996-04-25 2003-07-02 Nissan Chemical Industries, Limited Ethylene derivatives and pest controlling agents
AU7726898A (en) 1997-05-22 1998-12-11 G.D. Searle & Co. Pyrazole derivatives as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
CA2293436C (en) 1997-06-12 2010-10-26 Rhone-Poulenc Rorer Limited Imidazolyl-cyclic acetals as tnf inhibitors
AU7966198A (en) 1997-06-13 1998-12-30 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
CA2306811A1 (en) 1997-10-14 1999-04-22 Yoshiyuki Aoki Piperazine compounds and medicinal use thereof
AR017219A1 (es) 1997-12-19 2001-08-22 Smithkline Beecham Corp Derivados de imidazol 1,4,5 sustituidos, composiciones que los comprenden, procedimiento para la preparacion de dichos derivados, uso de los derivados parala manufactura de un medicamento
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
WO2000010563A1 (en) * 1998-08-20 2000-03-02 Smithkline Beecham Corporation Novel substituted triazole compounds
ATE258055T1 (de) 1998-11-04 2004-02-15 Smithkline Beecham Corp Pyridin-4-yl oder pyrimidin-4-yl substituierte pyrazine
EP1208748A4 (en) * 1999-08-31 2002-11-20 Fujisawa Pharmaceutical Co PRESERVATIVES FOR ORGANS
US7253169B2 (en) 1999-11-12 2007-08-07 Gliamed, Inc. Aza compounds, pharmaceutical compositions and methods of use
US6417189B1 (en) * 1999-11-12 2002-07-09 Gpi Nil Holdings, Inc. AZA compounds, pharmaceutical compositions and methods of use
ES2249309T3 (es) 1999-11-23 2006-04-01 Smithkline Beecham Corp Compuestos de 3,4-dihidro-(1h)quinazolin-2-ona como inhibidores de csbp/p39 kinasa.
AU1783201A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
US6759410B1 (en) 1999-11-23 2004-07-06 Smithline Beecham Corporation 3,4-dihydro-(1H)-quinazolin-2-ones and their use as CSBP/p38 kinase inhibitors
JP2003514899A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４‐ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
US6583143B2 (en) * 2000-12-28 2003-06-24 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
DE60221392T2 (de) * 2001-05-24 2008-04-17 Eli Lilly And Co., Indianapolis Neue pyrrolderivate als pharmazeutische mittel
DE60315826T2 (de) 2002-04-19 2008-05-21 Smithkline Beecham Corp. Neue verbindungen
ES2278170T3 (es) 2002-07-09 2007-08-01 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Composiciones farmaceuticas de anticolinergicos e inhibidores de la quinasa p38 en el tratamiento de enfermedades respiratorias.
US7514441B2 (en) * 2002-08-26 2009-04-07 Takeda Pharmaceutical Company Limited Substituted pyrazolo [1,5-A]pyrimidines as calcium receptor modulating agents
AU2004210127B2 (en) * 2003-01-27 2009-10-01 Merck Sharp & Dohme Corp. Substituted pyrazoles, compositions containing such compounds and methods of use
DE602005006806D1 (de) * 2004-06-04 2008-06-26 Merck & Co Inc Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
PE20061351A1 (es) 2005-03-25 2007-01-14 Glaxo Group Ltd COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
US20090137550A1 (en) 2005-03-25 2009-05-28 Glaxo Group Limited Novel Compounds
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
KR20080002865A (ko) 2005-03-25 2008-01-04 글락소 그룹 리미티드 피리도[２,３-ｄ]피리미딘-７-온 및３,４-디히드로피리미도[４,５-ｄ]피리미딘-２(１ｈ)-온유도체의 제조 방법
CN101300232A (zh) * 2005-07-26 2008-11-05 默克公司 合成取代的吡唑的方法
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US20110195962A1 (en) * 2007-08-16 2011-08-11 Alcon Research, Ltd. Use of multi-pharmacophore compounds to treat nasal disorders
WO2009039387A1 (en) * 2007-09-20 2009-03-26 Wyeth Pyrazolo[5, 1-c] [1,2,4] triazines, methods for preparation and use thereof
CN101441969B (zh) 2007-11-23 2010-07-28 清华大学 场发射像素管
CN101441972B (zh) 2007-11-23 2011-01-26 鸿富锦精密工业（深圳）有限公司 场发射像素管
EP2402344A1 (en) * 2010-06-29 2012-01-04 Basf Se Pyrazole fused bicyclic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012154A1 (en) * 1990-12-31 1992-07-23 Fujisawa Pharmaceutical Co., Ltd. Imidazotriazine derivatives
US5356897A (en) * 1991-09-09 1994-10-18 Fujisawa Pharmaceutical Co., Ltd. 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines

Also Published As

Publication number Publication date
TW260669B (es) 1995-10-21
WO1994019350A1 (en) 1994-09-01
CA2156919A1 (en) 1994-09-01
AU6010894A (en) 1994-09-14
IL108562A0 (en) 1994-05-30
GB9303993D0 (en) 1993-04-14
HU9402459D0 (en) 1994-11-28
EP0686156A1 (en) 1995-12-13
KR100313615B1 (ko) 2002-05-30
CN1120840A (zh) 1996-04-17
JP3569917B2 (ja) 2004-09-29
EP0686156B1 (en) 2002-07-17
US5670503A (en) 1997-09-23
KR960701055A (ko) 1996-02-24
ZA94787B (en) 1994-09-08
JPH08507056A (ja) 1996-07-30
IL108562A (en) 1997-06-10
DE69430988D1 (de) 2002-08-22
CN1041929C (zh) 1999-02-03
PT686156E (pt) 2002-12-31
RU2124517C1 (ru) 1999-01-10
DK0686156T3 (da) 2002-11-11
HUT70832A (en) 1995-11-28
MX9401408A (es) 1994-08-31
AU681625B2 (en) 1997-09-04
DE69430988T2 (de) 2002-11-28
ATE220677T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
ES2176235T3 (es) Pirazolitriazinas con actividad inhibidora de la interleuquina-1 y delfactor de necrosis tumoral.
MX9800577A (es) Derivados de 4,5-diaril oxazol.
HU9601685D0 (en) 4,5-diaryloxazole derivatives
NO940737L (es)
MX9700308A (es) Derivados heterobiciclicos.
GR3035621T3 (en) New pyrimidone derivatives with antifungal activity
AU1070895A (en) Indole-derived arylpiperazines as ligands for 5HT1-like receptors 5HT1B and 5HT1D
GB9602029D0 (en) New heterocyclic compounds
MX9300552A (es) Derivados de etanolamina
GB9313330D0 (en) New compound and its preparation
HUP0103303A2 (hu) Imidazolvegyületek, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
AUPN952696A0 (en) New heterocyclic compounds
ATE155791T1 (de) Etoposid-derivate, ihre herstellung, ihre verwendung als medikament und ihre verwendung zur herstellung eines antikrebsmittels
ATE255102T1 (de) Benzothiophenderivate, ihre herstellung und verwendung als urokinase-inhibitoren
HUP0202340A2 (hu) Hatóanyagként kondenzált heterociklusos vegyületeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DE69124519D1 (de) Spiro[cycloalkylbenzen-1,1'-(1',2',3',4'-tetrahydroisoquinoline)] mit neuroprotektiven eigenschaften
HU9502647D0 (en) Benzo[f]quinoxalindione derivatives, their preparation and their use in drugs
CA2198875A1 (en) Quinazolinone pharmaceuticals and use thereof